Drugs showing promise in cancer trials reduce scarring for scleroderma

The findings could lead to repurposing drugs for patients with the sometimes-fatal condition.

11:38 AM

Author | Noah Fromson

Microscope lab notes
Michigan Medicine

Epigenetic drugs that have shown promise in cancer trials significantly reduce scarring in the cells of patients with scleroderma, an incurable and life-threatening autoimmune disease, a new study shows.

Scleroderma is a chronic disease that affects the immune system, causing a buildup of scar-like tissues in the skin and internal organs known as fibrosis. This process occurs when cells that make up connective tissue, called fibroblasts, produce too much collagen that causes the skin and organs of patients to harden – resulting in tissue damage and organ failure.

In a recent study, Michigan Medicine researchers focused on BETs, which are proteins that regulate gene expression by binding to modifications on proteins around which DNA wraps, a process called epigenetic regulation. Drugs targeting BETs, specifically an isoform called BRD4, have been developed by various pharmaceutical companies for cancer treatment.

Results published in JCI Insight reveal that drugs that inhibit BRD4, known to play a role in cancer, also affect fibrosis in scleroderma. Researchers tested BRD4 inhibitors on the skin fibroblasts of scleroderma patients and in mouse models of skin fibrosis. They found that the treatment stopped scarring in both human-derived cells and in animals.

The inhibitors used by Michigan Medicine researchers have shown promise for treating various cancers in preclinical studies. Specifically, one drug used in the recent study, called AZD5153, is being tested in a Phase I clinical trial for sarcomas and lymphomas.

"Through this study, we have uncovered a new class of epigenetic drugs that can be used in scleroderma fibrosis," said Pei-Suen Tsou (Eliza), Ph.D., senior author of the paper and a rheumatology researcher at Michigan Medicine. "If we can repurpose these drugs and get them through development more quickly, we can provide faster relief for patients who struggle with debilitating symptoms of this autoimmune disease. The process can typically take around 10 years, but our patients cannot wait that long."

The study is a collaborative effort with Michigan Medicine's Scleroderma Program. Tsou's team also found that a calcium signaling protein, called CaMKII, affects fibrosis in scleroderma, which researchers had previously not seen.

"Right now, we are doing some follow up studies to see if inhibitors of this protein can block scarring for scleroderma," Tsou said. "This opens up a brand-new direction for us to offer a novel target for this disease."

Additional authors include: Sirapa Vichaikul, B.S., Mikel Gurrea-Rubio, Ph.D., M. Asif Amin, M.D., Phillip L. Campbell, B.S., Qi Wu, Ph.D., Megan N. Mattichak, William D. Brodie, Pamela J. Palisoc, B.S., Mustafa Ali, B.S., Sei Muraoka, M.D., Ph.D., Jeffrey H. Ruth, Ph.D., Ellen N. Model, B.S., Dallas M. Rohraff, B.S., M.P.H., Jonatan L. Hervoso, B.S., Yang Mao-Draayer, M.D., Ph.D., David A. Fox, M.D., Dinesh Khanna, M.B.B.S., M.Sc., all of Michigan Medicine, and Amr H. Sawalha, M.D.,  University of Pittsburgh.

Paper Cited: "Inhibition of histone readers bromodomain extra-terminal proteins alleviates skin fibrosis in experimental models of scleroderma," JCI Insight. DOI: 10.1172/jci.insight.150871

More Articles About: Lab Notes Rheumatology Pulmonary Fibrosis Skin Conditions Drug Discovery Medication Interactions Lungs and Breathing
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories kids on the floor
Health Lab
Protecting children from poor air quality: 6 things to know
As smoke from Canada's historic wildfires triggers poor air quality alerts across the country, many parents worry about the impact on their child’s health, a national poll suggests. Here, a Michigan Medicine expert provides six ways to help reduce exposure.
Health Lab
Pulmonary embolism deaths, disparities high despite advancements in care
Despite these innovations, a Michigan Medicine study finds that the death rate for pulmonary embolism remains high and unchanged in recent years – more often killing men, Black patients and those from rural areas. The results are published in the Annals of the American Thoracic Society.
Blurry Operating Room
Health Lab
High levels of satisfaction, and low levels of regret, after gender affirming mastectomy
Recent research from the University of Michigan finds that in addition to changing lives, most patients are highly satisfied with their decision to undergo surgery long-term.
emergency room doors
Health Lab
‘Concerning’ CT scans may cause unnecessary hospitalization for some pulmonary embolism patients
Michigan Medicine research finds that some patients with PE, a blood clot in one or more pulmonary arteries, may be hospitalized unnecessarily due to computed tomography, or CT, imaging results rather than clinical risk factors.
older man on cpap machine sitting on bed
Health Lab
Controlling elevated carbon dioxide improves survival
A Michigan Medicine study finds controlling elevated carbon dioxide improves survival in patients.
older woman at table with medicine pills in front of her
Health Lab
"Deprescribing" medicines for older adults: Patient-provider dialogue needed
Stopping or reducing doses of prescription medicine, also called deprescribing, is something many older adults would like to do, and some have already done without medical guidance. Medication reviews could help.